论文部分内容阅读
目的:观察参附注射液联合西药治疗脓毒症休克大鼠的疗效。通过检测脓毒症休克大鼠用药前后血清sCD163数值的变化来了解参附注射液联合西药治疗脓毒症休克大鼠的疗效及重症脓毒症预后的评估。同时对在脓毒症中sCD163的作用机制进行探讨。方法:选取SPF级健康SD雄性大鼠60只,制作脓毒症休克大鼠模型,观察单用西药、单用参附注射液和参附注射液联合西药治疗前后大鼠sCD163、降钙素原、Lac的变化。结果:参附注射液联合西药治疗脓毒症休克大鼠前后6 h sCD163的变化具有统计学意义,联合治疗组优于单纯参附注射液或单纯西药组。结论:参附注射液能对抗细菌内毒素,对心肌细胞有正性肌力作用,sCD163做为临床脓毒症观察的敏感指标有望广泛应用于临床脓毒症休克治疗。
Objective: To observe the curative effect of Shenfu injection combined with western medicine on septic shock rats. To evaluate the effect of Shenfu injection combined with Western medicine on septic shock rats and the prognosis of severe sepsis by detecting the changes of serum sCD163 before and after sepsis in rats. At the same time, the mechanism of action of sCD163 in sepsis was discussed. Methods: Seventy SPF healthy SD male rats were selected to make septic shock rat model. Western medicine alone was used to observe the effect of sCD163, procalcitonin Lac changes. Results: The changes of sCD163 at 6 h before and after treatment with Shenfu injection combined with Western medicine were statistically significant. The combined treatment group was superior to the simple Shenfu injection or western medicine group. Conclusion: Shenfu injection can antagonize bacterial endotoxin and has positive inotropic effect on cardiomyocytes. As a sensitive indicator of clinical sepsis, sCD163 is expected to be widely used in clinical treatment of septic shock.